Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the meantime, some challenges and recommendations.

Martin SS, Metkus TS, Horne A, Blaha MJ, Hasan R, Campbell CY, Yousuf O, Joshi P, Kaul S, Miller M, Michos ED, Jones SR, Gluckman TJ, Cannon CP, Sperling LS, Blumenthal RS.

Am J Cardiol. 2012 Jul 15;110(2):307-13. doi: 10.1016/j.amjcard.2012.03.023. Epub 2012 Apr 10.

PMID:
22497674
2.

Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options.

Stone NJ, Bilek S, Rosenbaum S.

Am J Cardiol. 2005 Aug 22;96(4A):53E-59E. Review.

PMID:
16098845
3.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program..

J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. Review.

PMID:
15358046
4.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program..

Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):e149-61. Review.

5.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute.; American College of Cardiology Foundation.; American Heart Association..

Circulation. 2004 Jul 13;110(2):227-39. Review. Erratum in: Circulation. 2004 Aug 10;110(6):763.

6.
7.

Impact of the new National Cholesterol Education Program (NCEP) guidelines on patient management.

Harmel AP, Berra K.

J Am Acad Nurse Pract. 2003 Aug;15(8):350-60. Review.

PMID:
14509100
8.
9.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Evans M, Roberts A, Davies S, Rees A.

Drugs. 2004;64(11):1181-96. Review.

PMID:
15161326
10.

Management of cardiovascular risk: the importance of meeting lipid targets.

Gotto AM Jr, Moon JE.

Am J Cardiol. 2012 Jul 1;110(1 Suppl):3A-14A. doi: 10.1016/j.amjcard.2012.04.002. Review.

PMID:
22697390
11.

Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline.

Stone NJ, Robinson JG, Lichtenstein AH, Goff DC Jr, Lloyd-Jones DM, Smith SC Jr, Blum C, Schwartz JS; 2013 ACC/AHA Cholesterol Guideline Panel..

Ann Intern Med. 2014 Mar 4;160(5):339-43. doi: 10.7326/M14-0126.

PMID:
24474185
12.
13.

Results of new statin trials: should the low-density lipoprotein cholesterol treatment guidelines be revised?

Ross AM, Ganiats TG.

Curr Atheroscler Rep. 2005 Feb;7(1):11-6. Review.

PMID:
15683596
14.
15.

Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines.

Clearfield M, Downs JR, Lee M, Langendorfer A, McConathy W, Gotto AM Jr.

Am J Cardiol. 2005 Dec 15;96(12):1674-80. Epub 2005 Nov 2.

PMID:
16360356
16.

Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial.

de Lemos JA, Wiviott SD, Murphy SA, Blazing MA, Lewis EF, Califf RM, Pfeffer MA, Braunwald E.

Am J Cardiol. 2006 Sep 15;98(6):739-42. Epub 2006 Jul 26.

PMID:
16950174
18.

Adult treatment panel III and the management of dyslipidemia risk factors.

Stein EA.

Postgrad Med. 2002 Oct;112(4 Suppl):12-7. doi: 10.3810/pgm.10.2002.suppl20.106. Review.

PMID:
19667595
19.

Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.

Daskalopoulou SS, Mikhailidis DP.

Curr Med Res Opin. 2006 Mar;22(3):511-28. Review.

PMID:
16574035
20.

Rationale for aggressive lipid lowering in high-risk patients.

Cohen JD.

J Am Osteopath Assoc. 2011 Apr;111(4 Suppl 3):eS7-12. Review.

PMID:
21593473

Supplemental Content

Support Center